CHICAGO--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today the interim results of a 10-week study comparing CLENZIderm M.D.™ Acne Therapeutic Systems’ 3-step acne system for normal-to-oily skin to a leading combination benzoyl peroxide (BPO)/clindamycin antibiotic product at the American Academy of Dermatology Summer Meeting in Chicago. The data, compiled from 69 patients at week 6 of the study, show that patients with mild-to-moderately severe acne experienced comparable reductions in inflammatory and non-inflammatory lesions when using the CLENZIderm M.D. System which offers a new solubilized BPO technology.
